By looking at the same biomarkers and stratifying the patients by disease progression, we found a significantly lower ER expression (P = 0.02) and lower HER2 CN/cent17 CN ratio (P = 0.009) in samples from patients with later metastatic disease compared to those without metastasis (Fig. 2A). This evidence concerns the gene ESR1 and metastatic neoplasm.